跳至主要内容
临床试验/NCT00649415
NCT00649415已完成4 期

A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg BID, PRN In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

Pfizer1 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2003年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Pfizer
入组人数
154
试验地点
1
主要终点
Total pain relief were calculated as the summed weighted pain releif scores

研究概览

简要总结

To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 44 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • History of primary dysmenorrhea with moderate to severe menstrual cramping pain for which the patient took analgesic medication for at least three of six previous menstrual cycles before enrollment
  • Subjects were to have been in good health and were to have had a complete physical exam (including a pap smear and an endovaginal or pelvic ultrasound, unless the subject had had these examinations performed within 6 months prior to the Screening Visit and the results were normal) prior to inclusion

排除标准

  • Subjects who were pregnant, lactating, breastfeeding or not using adequate methods of birth control

研究组 & 干预措施

Arm 1

Active Comparator

干预措施: piroxicam (Drug)

Arm 2

Active Comparator

干预措施: valdecoxib (Drug)

结局指标

主要结局

Total pain relief were calculated as the summed weighted pain releif scores

时间窗: 8 hours

次要结局

  • adverse events(approximately 5 days after treated cycle)
  • Subjects' global evaluation of the study drug(8 hours and 72 hours)
  • Summed pain intensity difference(8 hours)
  • laboratory analyses(screening)
  • Percent of subjects who took rescue medication(72 hours)
  • Percent of subjects who took the second dose of study medication(72 hours)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验